Loading…
Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its s...
Saved in:
Published in: | BMC cancer 2019-08, Vol.19 (1), p.774-774, Article 774 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3 |
---|---|
cites | cdi_FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3 |
container_end_page | 774 |
container_issue | 1 |
container_start_page | 774 |
container_title | BMC cancer |
container_volume | 19 |
creator | Kim, Chung Young Kim, Namju Choung, Ho-Kyung In Khwarg, Sang |
description | Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid.
A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from epiphora, and the height of tear meniscus was normalized in both eyes.
T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be treated effectively with a topical steroid. |
doi_str_mv | 10.1186/s12885-019-5986-5 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7d52fcd6b20747418ca1d38373e89cec</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A596594246</galeid><doaj_id>oai_doaj_org_article_7d52fcd6b20747418ca1d38373e89cec</doaj_id><sourcerecordid>A596594246</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3</originalsourceid><addsrcrecordid>eNptku2K1DAUhoso7rp6Af6RgCC7YNd8NG3qD2FZvwZHBB1_h9P0dCZL24xJqjtelBfhldk66zIFCSTh5HlfcpI3SR4zes6Yyl8ExpWSKWVlKkuVp_JOcsyygqU8o8Xdg_1R8iCEK0pZoai6nxwJJlQhJT9OrpdgvO2gJbUH28MaSdiFiB0Zp94FGwiE4IyFiDX5YeOGrDyEOPwcOqgIdhH6YHskpx-gNrsWfv96Tlbp64_sjEDd2d6G6CFa178kQAwEJB63zseHyb0G2oCPbtaT5OvbN6vL9-ny07vF5cUyNZJxmaJqeCFoJdBkDCFrKtWwLM8rVdAKOMo8QyGqulRVxkukrCll3dCKl0ZRMEacJIu9b-3gSm-nXv1OO7D6b8H5tQYfrWlRF7XkjanzitMiKzKmDLBaKFEIVKXByevV3ms7VB3WBvuxt3ZmOj_p7Uav3Xed50pIqUaD0xsD774NGKLubDDYttCjG4LmPC8zyoXMR_TpHl3DeDXbN250NBOuL2SZyzLj2USd_4caR42dNa7Hxo71meBsJhiZiNdxDUMIevHl85x9dsBuENq4Ca4dpt8Mc5DtQeNdCB6b2ydhVE9J1fuk6jGpekqqlqPmyeFb3ir-RVP8Abwh4_A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2269402356</pqid></control><display><type>article</type><title>Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Kim, Chung Young ; Kim, Namju ; Choung, Ho-Kyung ; In Khwarg, Sang</creator><creatorcontrib>Kim, Chung Young ; Kim, Namju ; Choung, Ho-Kyung ; In Khwarg, Sang</creatorcontrib><description>Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid.
A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from epiphora, and the height of tear meniscus was normalized in both eyes.
T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be treated effectively with a topical steroid.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-019-5986-5</identifier><identifier>PMID: 31387552</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Ado-Trastuzumab Emtansine - administration & dosage ; Ado-Trastuzumab Emtansine - adverse effects ; Adult ; Antibacterial agents ; Antibodies ; Antibody-drug conjugates ; Antineoplastic agents ; Antineoplastic Agents, Immunological - administration & dosage ; Antineoplastic Agents, Immunological - adverse effects ; Biological products ; Breast cancer ; Breast Neoplasms - complications ; Breast Neoplasms - diagnosis ; Breast Neoplasms - drug therapy ; Cancer ; Cancer metastasis ; Cancer treatment ; Case Report ; Case studies ; Complications and side effects ; Constriction, Pathologic ; Dexamethasone ; Diagnostic Imaging ; Dosage and administration ; Drug therapy ; Epidermal growth factors ; Epiphora ; Female ; Fluorescein ; Glucocorticoids ; Humans ; Kadcyla ; Lacrimal Apparatus Diseases - diagnosis ; Lacrimal Apparatus Diseases - etiology ; Lapatinib ; Liver ; Liver cancer ; Nasolacrimal duct stenosis ; Patient outcomes ; Stenosis ; Surgery ; Tobramycin ; Tomography, Optical Coherence ; Trastuzumab ; Trastuzumab emtansine</subject><ispartof>BMC cancer, 2019-08, Vol.19 (1), p.774-774, Article 774</ispartof><rights>COPYRIGHT 2019 BioMed Central Ltd.</rights><rights>The Author(s). 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3</citedby><cites>FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683558/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683558/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,36990,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31387552$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Chung Young</creatorcontrib><creatorcontrib>Kim, Namju</creatorcontrib><creatorcontrib>Choung, Ho-Kyung</creatorcontrib><creatorcontrib>In Khwarg, Sang</creatorcontrib><title>Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid.
A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from epiphora, and the height of tear meniscus was normalized in both eyes.
T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be treated effectively with a topical steroid.</description><subject>Ado-Trastuzumab Emtansine - administration & dosage</subject><subject>Ado-Trastuzumab Emtansine - adverse effects</subject><subject>Adult</subject><subject>Antibacterial agents</subject><subject>Antibodies</subject><subject>Antibody-drug conjugates</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Immunological - administration & dosage</subject><subject>Antineoplastic Agents, Immunological - adverse effects</subject><subject>Biological products</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - complications</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cancer</subject><subject>Cancer metastasis</subject><subject>Cancer treatment</subject><subject>Case Report</subject><subject>Case studies</subject><subject>Complications and side effects</subject><subject>Constriction, Pathologic</subject><subject>Dexamethasone</subject><subject>Diagnostic Imaging</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Epidermal growth factors</subject><subject>Epiphora</subject><subject>Female</subject><subject>Fluorescein</subject><subject>Glucocorticoids</subject><subject>Humans</subject><subject>Kadcyla</subject><subject>Lacrimal Apparatus Diseases - diagnosis</subject><subject>Lacrimal Apparatus Diseases - etiology</subject><subject>Lapatinib</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Nasolacrimal duct stenosis</subject><subject>Patient outcomes</subject><subject>Stenosis</subject><subject>Surgery</subject><subject>Tobramycin</subject><subject>Tomography, Optical Coherence</subject><subject>Trastuzumab</subject><subject>Trastuzumab emtansine</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNptku2K1DAUhoso7rp6Af6RgCC7YNd8NG3qD2FZvwZHBB1_h9P0dCZL24xJqjtelBfhldk66zIFCSTh5HlfcpI3SR4zes6Yyl8ExpWSKWVlKkuVp_JOcsyygqU8o8Xdg_1R8iCEK0pZoai6nxwJJlQhJT9OrpdgvO2gJbUH28MaSdiFiB0Zp94FGwiE4IyFiDX5YeOGrDyEOPwcOqgIdhH6YHskpx-gNrsWfv96Tlbp64_sjEDd2d6G6CFa178kQAwEJB63zseHyb0G2oCPbtaT5OvbN6vL9-ny07vF5cUyNZJxmaJqeCFoJdBkDCFrKtWwLM8rVdAKOMo8QyGqulRVxkukrCll3dCKl0ZRMEacJIu9b-3gSm-nXv1OO7D6b8H5tQYfrWlRF7XkjanzitMiKzKmDLBaKFEIVKXByevV3ms7VB3WBvuxt3ZmOj_p7Uav3Xed50pIqUaD0xsD774NGKLubDDYttCjG4LmPC8zyoXMR_TpHl3DeDXbN250NBOuL2SZyzLj2USd_4caR42dNa7Hxo71meBsJhiZiNdxDUMIevHl85x9dsBuENq4Ca4dpt8Mc5DtQeNdCB6b2ydhVE9J1fuk6jGpekqqlqPmyeFb3ir-RVP8Abwh4_A</recordid><startdate>20190806</startdate><enddate>20190806</enddate><creator>Kim, Chung Young</creator><creator>Kim, Namju</creator><creator>Choung, Ho-Kyung</creator><creator>In Khwarg, Sang</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190806</creationdate><title>Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report</title><author>Kim, Chung Young ; Kim, Namju ; Choung, Ho-Kyung ; In Khwarg, Sang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Ado-Trastuzumab Emtansine - administration & dosage</topic><topic>Ado-Trastuzumab Emtansine - adverse effects</topic><topic>Adult</topic><topic>Antibacterial agents</topic><topic>Antibodies</topic><topic>Antibody-drug conjugates</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Immunological - administration & dosage</topic><topic>Antineoplastic Agents, Immunological - adverse effects</topic><topic>Biological products</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - complications</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cancer</topic><topic>Cancer metastasis</topic><topic>Cancer treatment</topic><topic>Case Report</topic><topic>Case studies</topic><topic>Complications and side effects</topic><topic>Constriction, Pathologic</topic><topic>Dexamethasone</topic><topic>Diagnostic Imaging</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Epidermal growth factors</topic><topic>Epiphora</topic><topic>Female</topic><topic>Fluorescein</topic><topic>Glucocorticoids</topic><topic>Humans</topic><topic>Kadcyla</topic><topic>Lacrimal Apparatus Diseases - diagnosis</topic><topic>Lacrimal Apparatus Diseases - etiology</topic><topic>Lapatinib</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Nasolacrimal duct stenosis</topic><topic>Patient outcomes</topic><topic>Stenosis</topic><topic>Surgery</topic><topic>Tobramycin</topic><topic>Tomography, Optical Coherence</topic><topic>Trastuzumab</topic><topic>Trastuzumab emtansine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Chung Young</creatorcontrib><creatorcontrib>Kim, Namju</creatorcontrib><creatorcontrib>Choung, Ho-Kyung</creatorcontrib><creatorcontrib>In Khwarg, Sang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Science in Context</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Chung Young</au><au>Kim, Namju</au><au>Choung, Ho-Kyung</au><au>In Khwarg, Sang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2019-08-06</date><risdate>2019</risdate><volume>19</volume><issue>1</issue><spage>774</spage><epage>774</epage><pages>774-774</pages><artnum>774</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Trastuzumab emtansine (Kadcyla®, T-DM1) is an antibody-drug conjugate used to treat HER2 (human epidermal growth factor receptor 2) overexpressing metastatic breast cancer. In this report, we present the first case of lacrimal drainage system stenosis identified after T-DM1 administration, and its successful treatment with a topical steroid.
A 36-year-old female with metastatic breast cancer was referred for excessive tearing of both eyes. She previously underwent mastectomy and was treated with multiple anti-cancer regimens. However, metastases to liver and bone were identified and T-DM1 was administered. After 2 months, epiphora developed in both eyes and the patient was referred for ophthalmologic examination. The height of the tear meniscus was increased. The fluorescein dye disappearance test (FDDT) showed a delayed clearance in both eyes. Diagnostic lacrimal probing demonstrated a lower distal canalicular stenosis in both eyes. Dacryocystography indicated multiple focal narrowing of nasolacrimal duct in the right eye and diffused narrowing of nasolacrimal duct in the left eye. Topical eyedrop of tobramycin 0.3% and dexamethasone 0.1% were prescribed four times a day. After 2 months of treatment, the patient reported relief from epiphora, and the height of tear meniscus was normalized in both eyes.
T-DM1 administration in breast cancer treatment can induce lacrimal drainage system stenosis, which can be treated effectively with a topical steroid.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>31387552</pmid><doi>10.1186/s12885-019-5986-5</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2407 |
ispartof | BMC cancer, 2019-08, Vol.19 (1), p.774-774, Article 774 |
issn | 1471-2407 1471-2407 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_7d52fcd6b20747418ca1d38373e89cec |
source | Publicly Available Content (ProQuest); PubMed Central |
subjects | Ado-Trastuzumab Emtansine - administration & dosage Ado-Trastuzumab Emtansine - adverse effects Adult Antibacterial agents Antibodies Antibody-drug conjugates Antineoplastic agents Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Biological products Breast cancer Breast Neoplasms - complications Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Cancer Cancer metastasis Cancer treatment Case Report Case studies Complications and side effects Constriction, Pathologic Dexamethasone Diagnostic Imaging Dosage and administration Drug therapy Epidermal growth factors Epiphora Female Fluorescein Glucocorticoids Humans Kadcyla Lacrimal Apparatus Diseases - diagnosis Lacrimal Apparatus Diseases - etiology Lapatinib Liver Liver cancer Nasolacrimal duct stenosis Patient outcomes Stenosis Surgery Tobramycin Tomography, Optical Coherence Trastuzumab Trastuzumab emtansine |
title | Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T21%3A25%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lacrimal%20drainage%20system%20stenosis%20associated%20with%20Trastuzumab%20emtansine%20(Kadcyla%C2%AE,%20T-DM1)%20administration:%20a%20case%20report&rft.jtitle=BMC%20cancer&rft.au=Kim,%20Chung%20Young&rft.date=2019-08-06&rft.volume=19&rft.issue=1&rft.spage=774&rft.epage=774&rft.pages=774-774&rft.artnum=774&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-019-5986-5&rft_dat=%3Cgale_doaj_%3EA596594246%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5125-e8f2730b3ec41ea4fb8f1466b870ba2e564e33bd98b429e01f95df0b29c80acc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2269402356&rft_id=info:pmid/31387552&rft_galeid=A596594246&rfr_iscdi=true |